Quantcast
Last updated on April 17, 2014 at 14:33 EDT

Latest RNA Stories

2014-01-10 08:23:49

SEATTLE, Jan. 10, 2014 /PRNewswire/ -- PhaseRx, Inc., an RNA therapeutics company, today announced the appointment of Michael Houston, Ph.D., as its Vice President, Therapeutics Development. (Logo: http://photos.prnewswire.com/prnh/20140110/SF44129LOGO) Dr. Houston brings more than two decades of experience in the manufacturing and development of peptide and oligonucleotide-based therapeutics to PhaseRx. He has directed numerous programs ranging from research to GMP manufacture of...

2014-01-10 08:23:28

HOERSHOLM, Denmark and SAN DIEGO, Jan. 10, 2014 /PRNewswire/ -- Santaris Pharma A/S has announced today that they have signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris' Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform to research, develop and commercialize...

2014-01-08 12:29:45

LONDON, Jan. 8, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Analysis of MicroRNA Tools and Services Market Evolving microRNA Market Provides an Opportunity for Vendors of qRT-PCR and Functional ToolsThe study covers the analysis and forecasts of MicroRNA tools and services market globally for the period 2009 to 2017. The market is broadly classified into 2 major segments - tools and services. MicroRNA tools market is further segmented...

2014-01-08 08:28:05

HOERSHOLM, Denmark, SAN DIEGO, and MUNICH, Jan. 8, 2014 /PRNewswire/ -- Santaris Pharma A/S and BetaIsarna Therapeutics GmbH announced today that they have signed an agreement whereby Isarna gains access to Santaris' Locked Nucleic Acid (LNA) technology to further develop its next generation oligonucleotide product candidates. Under the terms of the agreement, Isarna obtains rights to utilize Santaris Pharma's proprietary LNA Drug Platform to discover, develop and commercialize...

2014-01-07 16:25:27

LA JOLLA, Calif., Jan. 7, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 8:30 AM PST at the Westin St. Francis Hotel in San Francisco, CA....

2014-01-07 08:29:46

SAN DIEGO, Jan. 7, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNA technologies for the treatment of rare orphan diseases, today announced that Joseph E. Payne, President & CEO will be presenting at the Biotech Showcase in San Francisco on Monday, January 13, 2014 at 11:30 a.m. PST, at the Parc 55 Wyndham Union Square Hotel in Track A - Hearst (3rd Floor). The presentation will provide a corporate overview and summarize the key accomplishments of 2013,...

2014-01-06 08:26:25

CAMBRIDGE, Mass., Jan. 6, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that President and founding Chief Executive Officer Stephane Bancel will present a company overview at the 32(nd) Annual J.P. Morgan Healthcare Conference. Bancel will focus on the potential of Moderna's mRNA therapeutics to transform drug...

2014-01-06 08:25:28

WESTBOROUGH, Mass., Jan. 6, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President and Chief Executive Officer, Dr. Geert Cauwenbergh, will present at the Biotech Showcase(TM) 2014 conference on Tuesday, January 14, 2014 at 9:30AM PST. Dr. Cauwenbergh will...

Scientists Uncover Most Detailed Picture Of Muscular Dystrophy Defect
2014-01-02 11:27:09

The Scripps Research Institute Scientists from the Florida campus of The Scripps Research Institute have revealed an atomic-level view of a genetic defect that causes a form of muscular dystrophy, myotonic dystrophy type 2, and have used this information to design drug candidates with potential to counter those defects—and reverse the disease. “This the first time the structure of the RNA defect that causes this disease has been determined,” said TSRI Associate Professor Matthew...

2013-12-24 13:35:52

Genetic screening identifies genes driving resistance with a guide RNA library Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types. CRISPR technology uses the DNA-cutting enzyme Cas9, with the help of a guide RNA sequence, to find and modify genetic targets. Scientists can easily engineer multiple new guide RNAs using standard molecular...


Latest RNA Reference Libraries

Brief Introduction To DNA Probes
2014-01-12 00:00:00

DNA probes help scientists to detect a specific gene in a long DNA sequence. According to Dr. Michael A. Pfaller, DNA probes are “single-stranded pieces of nucleic acid, labeled with a specific tracer (isotope, enzyme, or chromophore), that will hydrogen bond (hybridize) with complementary single-stranded pieces of DNA (or RNA) under the appropriate conditions of pH, temperature, and iconic strength.” The Foundation for Genomics and Population Health website has a helpful video about...

Caenorhabditis elegans
2014-01-12 00:00:00

Caenorhabditis elegans is a species of parasitic roundworm in the Nematoda phylum. It can be found in temperate regions, in many different areas of the world. It prefers to reside in nutrient rich soils. Its scientific name is derived from the Greek terms Caeno, meaning recent, rhabditis, meaning rod-like, and the Latin term elegans, which means elegant. It was first named by Maupas in 1900, but was not classified in the Caenorhabditis subgenus until 1952 by Osche. Caenorhabditis elegans...

Proceedings of the National Academy of Sciences
2012-05-29 11:19:42

The Proceedings of the National Academy of Sciences of the United States of America (PNAS) is a peer-reviewed scientific journal established in 1914 as the official journal of the US National Academy of Sciences. The first managing editor of the journal was mathematician Edwin Bidwell Wilson. As of May 2012, the editor-in-chief is Inder M. Verma. PNAS is published weekly in print, and daily online in PNAS Early Edition. The first issue of PNAS was published in 1915, and the journal...

Biophysical Journal
2012-05-28 10:08:02

The Biophysical Journal is a peer-reviewed scientific journal published biweekly by Cell Press on behalf of the Biophysical Society. It was established in 1960. The editor-in-chief is Edward Egelman. It covers all aspects of biophysics.  It is the leading international journal for original research in molecular, cellular, and system biophysics. Modern biophysics is a broad and rapidly advancing field encompassing the study of biological structures with a focus on mechanisms at the...

More Articles (5 articles) »